Trial Number
298-22
Condition
Cystic Fibrosis
Participant Age Range
12 years and older
Participant Gender
Any
Enrolling Participants
Yes
Overview
“A Phase 3, Open-label study evaluating the Long-term safety and Efficacy of VX-121 Combination Therapy in subjects with Cystic Fibrosis”
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.